Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

This study has been terminated.

(Termination of study was due to safety reasons)

Sponsor:

Information provided by (Responsible Party):

Bristol-Myers Squibb

ClinicalTrials.gov Identifier:

NCT01425970

First received: August 25, 2011

Last updated: May 13, 2014

Last verified: May 2014

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	August 2013
Primary Completion Date:	August 2013 (Final data collection date for primary outcome measure)